Eva Rossmann

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE Lenalidomide have both immunomodulatory and anti-angiogenic properties which could confer anti-cancer effects. The aim of this study was to assess the feasibility of combining lenalidomide with the standard treatment gemcitabine in pancreatic cancer patients with advanced disease. PATIENTS AND METHODS Eligible patients had locally advanced or(More)
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia Alemtuzumab (Campath, MabCampath) is a monoclonal antibody targeting the CD52 antigen. Recent guidelines recommend that this agent should be considered as first-line treatment in(More)
  • 1